Fig. 4From: Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot studyPercentage of parents reporting difficulties in cognitive skills from section 7 of the TAND checklist at baseline (D0), after treatment (D91), and after wash-out (D119)Back to article page
